Department of Medical Nutrition, Graduate School of East-West Medical Science, Kyung Hee University, Yongin 17104, South Korea.
Research Institute of Medical Nutrition, Kyung Hee University, Seoul 02447, South Korea.
Food Funct. 2024 Aug 12;15(16):8448-8458. doi: 10.1039/d4fo00535j.
Obesity is a common metabolic disease characterized by abnormal fat accumulation. It contributes to health issues, such as type 2 diabetes, cardiovascular disease, and dyslipidemia, necessitating continuous management through diet and physical activity. Probiotics, particularly IDCC 4301 ( Fit™), have shown promise in positively regulating the gut microbiota. Therefore, this study aimed to evaluate the anti-obesity effect of IDCC 4301 ( Fit™) in obese women. A randomized, double-blind, placebo-controlled, parallel-arm study was performed in 99 volunteers with a body mass index (BMI) of 25-30 kg m. The participants were randomly assigned to probiotics ( = 49, >5.0 × 10 CFU day) or placebo ( = 50) groups. Body fat, lipid profiles, and adipokine levels were assessed at baseline and at 12 weeks. After 12 weeks, changes in total fat (placebo -0.16 ± 0.83 kg; probiotics -0.45 ± 0.83 kg; = 0.0407), trunk fat (placebo -0.03 ± 0.50 kg; probiotics -0.22 ± 0.51 kg; = 0.0200), and serum triglyceride concentration (placebo 13 ± 60 mg dL; probiotics -15 ± 62 mg dL; = 0.0088) were significantly different between the groups. The difference in total fat mass change between groups among postmenopausal women was greater than that of all women. A significant positive correlation was found between the change in total fat mass and log leptin/adiponectin ratio ( = 0.371, = 0.0112) in the probiotics group. In addition, BMI (26.6 ± 1.9 kg m to 26.4 ± 2.0 kg m, = 0.0009) and leg fat (42 ± 5% to 41 ± 5%, = 0.0006) significantly decreased in the probiotics group after 12 weeks, but there was no difference in the placebo group. In conclusion, IDCC 4301 ( Fit™) may be associated with body fat loss through changes in metabolic health parameters, such as serum triglyceride and adipokine levels. The clinical trial registry number is KCT0007425 (https://cris.nih.go.kr).
肥胖是一种常见的代谢性疾病，其特征是脂肪异常堆积。它会导致 2 型糖尿病、心血管疾病和血脂异常等健康问题，因此需要通过饮食和体育锻炼来持续管理。益生菌，特别是 IDCC 4301（Fit），已被证明可以积极调节肠道微生物群。因此，本研究旨在评估 IDCC 4301（Fit）对肥胖女性的抗肥胖作用。一项随机、双盲、安慰剂对照、平行臂研究在 99 名体重指数（BMI）为 25-30 kg m 的志愿者中进行。参与者被随机分配到益生菌组（=49，>5.0×10 CFU 天）或安慰剂组（=50）。在基线和 12 周时评估体脂肪、血脂谱和脂肪因子水平。12 周后，比较总脂肪（安慰剂-0.16±0.83kg；益生菌-0.45±0.83kg；=0.0407）、躯干脂肪（安慰剂-0.03±0.50kg；益生菌-0.22±0.51kg；=0.0200）和血清甘油三酯浓度（安慰剂 13±60mg dL；益生菌-15±62mg dL；=0.0088）的变化。绝经后妇女中，两组之间总脂肪量变化的差异大于所有妇女。益生菌组总脂肪量变化与瘦素/脂联素比值的变化呈显著正相关（=0.371，=0.0112）。此外，益生菌组 BMI（26.6±1.9kg m 至 26.4±2.0kg m，=0.0009）和腿部脂肪（42±5%至 41±5%，=0.0006）在 12 周后显著降低，但安慰剂组无差异。总之，IDCC 4301（Fit）可能通过改变血清甘油三酯和脂肪因子等代谢健康参数与体脂肪减少有关。临床试验注册号为 KCT0007425（https://cris.nih.go.kr）。
